The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer

Asian Journal of Andrology 2026 Open access

Read full text
Authors: Qian Wang, Ming Zhang, Q. Zhu, Hong Zeng, Jindong Dai, Ke Colin Huang, Si-Cheng Wan, Shi Yi-fu, Xing-Ming Zhang, Hao Zeng, Pengfei Shen
DOI: 10.4103/aja202520
Cited by: 0
References: 22

Abstract

To evaluate the prognostic significance of prostate-specific antigen (PSA) decline depth and duration in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) undergoing abiraterone treatment. We retrospectively analyzed data from 153 high-risk patients with mHSPC receiving first-line abiraterone therapy. Patients were stratified based on PSA dynamics during treatment. Kaplan-Meier survival analysis and Cox proportional hazards regression were used to assess the associations between PSA decline patterns, PSA progression-free survival (PSA-PFS), radiographic PFS (rPFS), and overall survival (OS). Among the 153 patients, 85 exhibited PSA nadir 4 ng ml -1 . During abiraterone treatment, PSA nadir

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
Asian Journal of Andrology
Volume
28
Issue
3
Pages
304–309
Publication date
8 January 2026
Language
EN